Diabetes and Heart Disease

The Link Between Diabetes and Heart Disease: Why They Are So Often Found Together

Cardiovascular disease is the leading cause of death in people with diabetes — responsible for approximately 50% of all deaths among people with Type 2 diabetes and a major cause of morbidity and mortality in Type 1 diabetes as well. The connection between diabetes and heart disease is not coincidental: the same metabolic environment that produces elevated blood glucose also directly damages blood vessel walls, accelerates atherosclerosis, promotes blood clotting, and creates the inflammatory, proatherogenic conditions that lead to heart attack and stroke. Understanding why diabetes and heart disease are so closely linked — and what can be done to interrupt this connection — is one of the most important areas of diabetes management. Our guide on what is diabetes provides the foundational overview of the condition; this article focuses on the specific cardiovascular consequences of diabetes and the evidence-based strategies for reducing heart disease risk in people with diabetes.

Diabetes and Heart Disease: The Numbers Adults with diabetes are 2–4 times more likely to die from heart disease than adults without diabetes. Cardiovascular disease — including heart attack, stroke, and heart failure — accounts for approximately 50% of deaths in people with Type 2 diabetes. People with diabetes develop heart disease at younger ages, have more severe disease at presentation, and have worse outcomes after cardiac events (higher rates of heart failure, arrhythmias, and death) than people without diabetes who have heart attacks.

How High Blood Sugar Damages the Heart and Blood Vessels

The cardiovascular damage from diabetes operates through multiple simultaneous mechanisms that together produce a profoundly hostile vascular environment:

Endothelial dysfunction: The endothelium — the single-cell layer lining the interior of all blood vessels — is the first target of chronically elevated blood glucose. High glucose produces excess reactive oxygen species (free radicals), reduces nitric oxide (the molecule that keeps blood vessels relaxed and open), promotes inflammation, and directly damages endothelial cell DNA and mitochondria. The result is endothelial dysfunction — a state in which the blood vessel walls lose their normal protective, anti-inflammatory, anti-clotting properties and instead become a site of inflammation and atherosclerotic plaque initiation. Endothelial dysfunction is detectable before any structural atherosclerosis develops and represents the earliest stage of diabetes-related cardiovascular disease.

Accelerated atherosclerosis: The inflammatory, endothelial-damaging milieu of chronic hyperglycemia accelerates the formation of atherosclerotic plaques — the fatty deposits within arterial walls that narrow blood vessels and, when they rupture, trigger heart attacks and strokes. People with Type 2 diabetes develop atherosclerosis at younger ages and with greater severity than non-diabetic adults, and the plaques that form in diabetic arteries are more prone to inflammation and rupture than plaques in non-diabetic arteries.

Dyslipidemia: Insulin resistance is closely associated with a characteristic lipid pattern — elevated triglycerides, reduced HDL (“good”) cholesterol, and a predominance of small, dense LDL particles that are more atherogenic (more capable of penetrating arterial walls and being oxidized) than large, buoyant LDL. This “diabetic dyslipidemia” substantially amplifies cardiovascular risk beyond what elevated LDL alone would produce. Our guide on metabolic syndrome and diabetes covers this lipid pattern in the context of the full metabolic syndrome cluster.

Hypertension: High blood pressure occurs in approximately 70–80% of adults with Type 2 diabetes and acts synergistically with the endothelial dysfunction and dyslipidemia of diabetes to accelerate atherosclerosis. Elevated blood pressure mechanically stresses arterial walls, promotes endothelial damage, and accelerates plaque formation — making blood pressure control one of the highest-impact cardiovascular risk reduction interventions in diabetes. Our guide on what is insulin resistance covers the mechanisms linking insulin resistance to hypertension.

Procoagulant state: Diabetes promotes a prothrombotic (clot-forming) state through multiple mechanisms — elevated platelet reactivity, increased fibrinogen, reduced fibrinolysis (clot breakdown), and endothelial dysfunction that exposes the clot-triggering subendothelial matrix. This procoagulant state means that when an atherosclerotic plaque ruptures in a diabetic artery, the resulting blood clot is more likely to be large, more likely to be resistant to dissolution, and more likely to produce a complete arterial occlusion (and therefore a larger, more damaging heart attack or stroke).

doctor reviewing cardiac risk assessment with a diabetic patient including blood pressure lipids and A1C results — Comprehensive cardiovascular risk management in diabetes addresses blood glucose, blood pressure, lipids, and smoking simultaneously to reduce heart attack and stroke risk.

Types of Heart Disease More Common in People With Diabetes

Diabetes elevates risk for all major forms of cardiovascular disease, but the pattern of cardiac involvement has some distinctive features in the diabetic population:

Coronary artery disease (CAD): Narrowing of the coronary arteries from atherosclerosis is the primary cardiovascular complication of diabetes and the most common cause of heart attacks in diabetic patients. Importantly, coronary artery disease in people with diabetes often develops as “silent” ischemia — reduced blood flow to the heart muscle that does not produce the typical chest pain symptoms that prompt evaluation in non-diabetic patients, because diabetic peripheral and autonomic neuropathy can impair the pain sensation that normally warns of cardiac ischemia. People with diabetes who develop unexplained fatigue, shortness of breath on exertion, or jaw or shoulder pain should be evaluated for coronary artery disease even without classic chest pain.
Heart failure: People with diabetes have 2–5 times higher rates of heart failure than non-diabetic adults. “Diabetic cardiomyopathy” — a form of heart muscle dysfunction that occurs independently of coronary artery disease and hypertension — is driven by direct effects of chronically elevated glucose on heart muscle cells, including glucose toxicity, oxidative stress, inflammation, fibrosis, and impaired calcium handling that stiffen the heart muscle and impair its ability to fill and pump normally. Heart failure in diabetes tends to present as “heart failure with preserved ejection fraction” (HFpEF) — where the heart pumps out an adequate fraction of blood with each beat but cannot fill properly due to stiffness.
Stroke: Adults with diabetes have a 2–4 times higher risk of stroke than adults without diabetes, driven by the same combination of accelerated atherosclerosis, hypertension, dyslipidemia, and procoagulant state that produces coronary artery disease. Atrial fibrillation — which substantially raises stroke risk — is also more common in people with diabetes. Our guide on Type 2 diabetes symptoms and complications covers the full spectrum of diabetes-related health consequences.
Peripheral arterial disease (PAD): Atherosclerosis in the arteries of the legs and feet reduces blood flow to the extremities, producing leg pain on exertion (claudication), slow-healing wounds, and in severe cases limb-threatening ischemia. PAD in people with diabetes is compounded by diabetic peripheral neuropathy — meaning that the pain warning of reduced blood flow may be absent, and wounds may go unnoticed until they are far advanced. Our guide on slow wound healing and diabetes covers the intersection of PAD and neuropathy in diabetic foot disease.

Cardiovascular Risk Reduction in Diabetes: The Evidence-Based Priorities

The management of cardiovascular risk in diabetes is now one of the best-supported areas of evidence-based medicine, with multiple large outcome trials demonstrating that specific interventions reduce cardiovascular events and cardiovascular mortality in people with diabetes:

Blood pressure control: The target blood pressure for adults with diabetes is below 130/80 mmHg, based on evidence that this level reduces cardiovascular and kidney disease outcomes relative to more lenient targets. ACE inhibitors and angiotensin receptor blockers (ARBs) are preferred first-line antihypertensives in diabetes because of their additional kidney-protective properties. Blood pressure management is the single most important intervention for stroke prevention in people with diabetes.
Statin therapy: High-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) is recommended for all adults with diabetes aged 40–75 regardless of baseline LDL level, based on large trial evidence of cardiovascular event reduction. People with diabetes over 75 should discuss statin therapy with their provider based on individual risk-benefit assessment. LDL target is below 70 mg/dL for high-risk diabetic patients and below 55 mg/dL for very high-risk patients (those with established cardiovascular disease).
GLP-1 receptor agonists and SGLT-2 inhibitors with proven cardiovascular benefit: Several diabetes medications have now been shown in large randomized trials to reduce cardiovascular events and mortality independently of their glucose-lowering effect. Semaglutide (Ozempic), liraglutide (Victoza), and dulaglutide (Trulicity) — GLP-1 receptor agonists — reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with Type 2 diabetes and established cardiovascular disease or high cardiovascular risk. Empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) — SGLT-2 inhibitors — reduce cardiovascular death and hospitalization for heart failure. These medications are now recommended as preferred agents for people with Type 2 diabetes who have established cardiovascular disease or significant cardiovascular risk, independent of A1C considerations.
Smoking cessation: Smoking is the most modifiable cardiovascular risk factor, and its combination with diabetes produces multiplicative (not merely additive) cardiovascular risk. Smoking cessation is an urgent priority for any person with diabetes who smokes.

Heart Disease Screening for People With Diabetes

Given the dramatically elevated cardiovascular risk in diabetes, proactive cardiac screening is a standard component of comprehensive diabetes care — even in the absence of symptoms. The following screening elements are recommended for adults with diabetes:

Blood pressure measurement at every clinical visit, with home blood pressure monitoring encouraged for people with elevated readings or those adjusting antihypertensive medications. Our guide on diabetes and high blood pressure covers the management of hypertension in diabetes in detail.
Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) at diagnosis and annually, to assess dyslipidemia and guide statin therapy decisions. Our guide on diabetes and cholesterol covers lipid management in diabetes.
A1C every 3–6 months to assess glycemic control — the modifiable factor most directly linked to the endothelial damage and atherosclerosis acceleration mechanisms described above. Our guide on what the A1C test means covers interpretation and targets.
10-year cardiovascular risk assessment using validated tools (ASCVD risk calculator or equivalent) at least every 5 years in lower-risk patients, or more frequently as risk factors change. All adults with Type 2 diabetes aged 40–75 are considered at high cardiovascular risk regardless of calculated risk score, and are candidates for high-intensity statin therapy.
Resting electrocardiogram (ECG) in adults with symptoms, hypertension, or other cardiovascular risk factors, to detect silent ischemia, left ventricular hypertrophy, or arrhythmias. Stress testing and coronary artery calcium scoring may be indicated for higher-risk individuals — discussion with a cardiologist is appropriate for anyone with multiple cardiovascular risk factors or suggestive symptoms.

Lifestyle Interventions That Protect Both Blood Sugar and Heart Health

The lifestyle strategies that improve blood glucose control also directly benefit cardiovascular health — often through overlapping mechanisms — making comprehensive lifestyle modification among the most powerful tools for simultaneous diabetes and heart disease risk management:

Dietary patterns: The Mediterranean diet — emphasizing vegetables, legumes, whole grains, fish, olive oil, and nuts, while limiting red meat, refined carbohydrates, and processed foods — has the strongest evidence base for cardiovascular disease prevention and also improves glycemic control in people with Type 2 diabetes. Multiple large randomized trials (including the PREDIMED trial) have shown that a Mediterranean dietary pattern reduces cardiovascular events (heart attack, stroke, cardiovascular death) by approximately 30% in high-risk populations. The DASH diet (Dietary Approaches to Stop Hypertension) — which emphasizes fruits, vegetables, whole grains, and low-fat dairy while limiting sodium — is similarly beneficial for blood pressure and cardiovascular health. Our guides on what foods raise blood sugar and blood sugar after meals provide the dietary framework for managing glucose alongside heart health.

Physical activity: Regular aerobic exercise improves endothelial function (reversing the early stages of vascular damage), reduces blood pressure, improves the dyslipidemia of diabetes (raising HDL and reducing triglycerides), reduces inflammation, and improves insulin sensitivity — addressing multiple cardiovascular risk factors simultaneously. The AHA and ADA recommend at least 150 minutes per week of moderate-intensity aerobic activity for cardiovascular benefit in people with diabetes. Resistance training, which builds muscle mass and improves insulin sensitivity, provides complementary cardiovascular benefits through different mechanisms. Our guide on sedentary lifestyle and blood sugar covers the mechanisms of exercise-induced metabolic improvement.

Weight management: Even modest weight loss (5–10% of body weight) produces meaningful improvements in blood pressure, triglycerides, HDL, fasting glucose, and inflammatory markers — reducing multiple cardiovascular risk factors simultaneously. Weight loss reduces visceral fat (which drives insulin resistance and inflammatory cardiovascular risk) and reduces the mechanical and metabolic burden on the heart. Our guide on belly fat and diabetes risk covers the cardiovascular importance of visceral fat reduction specifically.

Diabetic Cardiomyopathy: When Diabetes Damages the Heart Muscle Directly

Beyond the arterial disease and risk factor amplification described above, diabetes can produce direct damage to the heart muscle itself — a condition termed diabetic cardiomyopathy — through mechanisms that are independent of atherosclerosis and hypertension. Diabetic cardiomyopathy is increasingly recognized as an important cardiovascular complication of diabetes that contributes to the elevated heart failure rates seen in diabetic populations. The mechanisms of diabetic cardiomyopathy include:

Glucose toxicity to cardiomyocytes: Chronically elevated blood glucose produces oxidative stress, mitochondrial dysfunction, and inflammation in heart muscle cells — impairing their contractile function and energy metabolism
Advanced glycation endproducts (AGEs): The binding of glucose to structural proteins produces AGEs that stiffen the collagen matrix of the heart, reducing its ability to relax between beats and impairing diastolic filling — producing the “diastolic dysfunction” that is often the earliest detectable cardiac abnormality in people with diabetes even before symptoms develop
Cardiac autonomic neuropathy: Diabetic neuropathy affecting the nerves that regulate heart rate and blood pressure produces abnormal heart rate variability, resting tachycardia, and impaired cardiovascular reflexes — all of which increase cardiovascular risk and complicate the management of other cardiac conditions. Our guide on tingling feet and diabetes discusses peripheral neuropathy; cardiac autonomic neuropathy is the most clinically significant form of autonomic neuropathy and warrants specific evaluation in people with long-standing or poorly controlled diabetes

The SGLT-2 inhibitor class of diabetes medications has shown particularly impressive benefits for diabetic cardiomyopathy and heart failure — empagliflozin (Jardiance) and dapagliflozin (Farxiga) both reduce hospitalizations for heart failure and cardiovascular mortality in people with Type 2 diabetes and heart failure, making them preferred agents for people with both conditions. These medications appear to work partly through non-glucose mechanisms — including reduction of cardiac preload and afterload, improvement of myocardial metabolism, and anti-inflammatory effects on heart muscle — making them effective even in heart failure patients with normal blood glucose. Our guide on what is insulin resistance provides the metabolic context for understanding how insulin resistance affects cardiac muscle function in the ways that SGLT-2 inhibitors appear to address.

The ACCORD, ADVANCE, and UKPDS Evidence: What Glycemic Control Does for the Heart Large outcome trials have established that tight glycemic control reduces microvascular complications (kidney, eye, nerve disease) convincingly in both Type 1 and Type 2 diabetes. The cardiovascular benefit of tight glucose control in Type 2 diabetes is more nuanced: the UKPDS showed a trend toward cardiovascular benefit with early intensive control, while the ACCORD trial found that very aggressive glucose lowering in high-risk older adults (targeting A1C below 6%) increased cardiovascular mortality. The current consensus is that A1C targets below 7% are appropriate for most adults, that targets should be individualized (especially in older adults), and that the specific medications used to achieve glucose control matter as much as the glucose value itself — with GLP-1 agonists and SGLT-2 inhibitors providing cardiovascular benefit beyond their glucose-lowering effects.

Recognizing Heart Attack and Stroke Symptoms in People With Diabetes

People with diabetes — particularly those with long-standing disease or significant autonomic neuropathy — are at elevated risk for “silent” heart attacks (myocardial infarctions without the typical severe chest pain, because diabetic neuropathy impairs the pain signals that normally warn of cardiac ischemia). Recognizing the atypical warning signs of cardiac events in people with diabetes is potentially life-saving:

Unexplained shortness of breath — with exertion or at rest — may be the primary symptom of a heart attack or developing heart failure in someone with diabetes who lacks typical chest pain
Unusual or extreme fatigue — particularly new-onset fatigue during activities previously performed without difficulty — can signal reduced cardiac output from coronary artery disease or cardiomyopathy
Jaw, shoulder, or arm pain — particularly the left arm or jaw — even without chest pain, are recognized anginal equivalents that warrant urgent cardiac evaluation
Sudden nausea or vomiting — without other explanation — can be a cardiac event symptom
Palpitations or irregular heartbeat — which may represent atrial fibrillation (a significant stroke risk factor that is more common in people with diabetes)

For stroke, all adults — with or without diabetes — should know the FAST acronym: Face drooping, Arm weakness, Speech difficulty, Time to call emergency services. Stroke requires emergency treatment within hours to minimize brain damage, and time-to-treatment is the most important determinant of outcome. People with diabetes who have multiple cardiovascular risk factors should discuss aspirin therapy, anticoagulation for atrial fibrillation, and other stroke prevention strategies with their healthcare team. Our guide on what is normal blood sugar provides the context for understanding how glucose control relates to the vascular damage that underlies stroke risk in diabetes, and our guide on Type 2 diabetes symptoms and diagnosis covers the broader clinical picture of diabetes and its complications management.

People with diabetes who have cardiovascular symptoms — including any of the atypical presentations described above — should not dismiss them as diabetes-related fatigue or neuropathy without cardiac evaluation. The threshold for seeking urgent evaluation should be lower in people with diabetes than in the general population precisely because typical warning symptoms may be absent or blunted. A brief evaluation that turns out to be benign is far preferable to a delayed diagnosis of a treatable cardiac event.

Cardioprotective Diabetes Medications: A Paradigm Shift Before 2015, diabetes medications were evaluated only on their ability to lower blood glucose. The EMPA-REG OUTCOME trial (2015) changed this paradigm entirely: empagliflozin not only lowered glucose but reduced cardiovascular death by 38% and hospitalization for heart failure by 35% in people with Type 2 diabetes and established cardiovascular disease. Similar landmark trials followed for other GLP-1 agonists and SGLT-2 inhibitors. Today, for people with Type 2 diabetes and existing cardiovascular disease or high cardiovascular risk, the question is no longer only “which medication lowers A1C” — it is “which medication lowers A1C while also protecting the heart and kidneys?” The answer consistently points to GLP-1 agonists and SGLT-2 inhibitors as preferred agents in this population.

Sources: American Diabetes Association. “Cardiovascular Disease and Risk Management.” Diabetes Care 2024. | American Heart Association — Diabetes Complications and Risks. | NIDDK — Heart Disease and Diabetes. | Mayo Clinic — Diabetes and Heart Disease. | Marso SP, et al. “Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes.” NEJM 2016.